SI-BONE, Inc. (NASDAQ:SIBN) SVP Michael A. Pisetsky Sells 3,128 Shares

SI-BONE, Inc. (NASDAQ:SIBN) SVP Michael A. Pisetsky sold 3,128 shares of the stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $14.14, for a total value of $44,229.92. Following the sale, the senior vice president now directly owns 244,878 shares of the company’s stock, valued at approximately $3,462,574.92. This represents a 1.26 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

SI-BONE Trading Down 1.0 %

Shares of SIBN stock opened at $13.47 on Friday. SI-BONE, Inc. has a twelve month low of $11.70 and a twelve month high of $19.16. The company has a market capitalization of $571.84 million, a price-to-earnings ratio of -14.64 and a beta of 1.02. The firm has a 50-day moving average price of $16.14 and a 200 day moving average price of $14.71. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22.

SI-BONE (NASDAQ:SIBN) last announced its earnings results on Monday, February 24th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. The firm had revenue of $49.00 million for the quarter, compared to analyst estimates of $48.87 million. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. Research analysts forecast that SI-BONE, Inc. will post -0.78 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SIBN has been the subject of a number of recent analyst reports. Needham & Company LLC raised their price objective on shares of SI-BONE from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Tuesday, February 25th. Truist Financial reaffirmed a “buy” rating and set a $22.00 price target (up from $18.00) on shares of SI-BONE in a research note on Tuesday, February 25th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $25.00 target price on shares of SI-BONE in a research report on Tuesday, February 25th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $24.40.

Hedge Funds Weigh In On SI-BONE

Several large investors have recently added to or reduced their stakes in SIBN. FMR LLC lifted its holdings in shares of SI-BONE by 103.6% during the 3rd quarter. FMR LLC now owns 2,354 shares of the company’s stock worth $33,000 after acquiring an additional 1,198 shares during the period. Virtus Fund Advisers LLC acquired a new position in SI-BONE during the fourth quarter worth approximately $40,000. Mainstream Capital Management LLC purchased a new position in SI-BONE during the fourth quarter worth approximately $53,000. R Squared Ltd acquired a new position in shares of SI-BONE in the 4th quarter valued at $73,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of SI-BONE during the 4th quarter valued at $97,000. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.